Health ❯ Mental Health ❯ Depression

Treatment-Resistant Depression

Clinical Trials Ketamine Ketamine Therapy Esketamine Ketogenic Diet Psychedelic Therapy Spravato Music Therapy Nerve Stimulation Therapy SPRAVATO Nasal Spray Treatment Nasal Spray Treatments Patient Experiences Ketamine Risks Ketamine Addiction Ketamine Research Psilocybin Nitrous Oxide Treatment Nitrous Oxide Psilocybin Use Psilocybin Treatment Clinical Research Neuroplastogens Brain Implant Technology Immunotherapy Neuroplasticity Psilocybin Therapy Investigational Drugs

Psilocybin Reorganizes Brain Activity to Match a Person’s Experience

A Nature paper shows brain patterns shift to track immediate context and subjective state, offering neural markers that could inform therapeutic use.

Lilly Expands Neuroscience Pipeline With $2.8 Billion Purchase of AtaiBeckley

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

IL‑6 Blocker Tocilizumab Shows Early Promise for Inflammation‑Linked Depression

FDA Clears Motif Neurotech Trial of At-Home Brain Implant for Treatment-Resistant Depression

Psilocybin Therapy Clears Second Phase 3 Test as Compass Pathways Preps FDA Bid

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Small Trial Finds Short-Term Antidepressant Effect From Ketogenic Diet in Treatment-Resistant Depression

Meta-Analysis Finds Nitrous Oxide Offers Rapid, Short-Lived Relief for Depression

IV Ketamine Shows Faster, Larger Gains Than Esketamine Nasal Spray in New Real‑World Depression Study